Integrated Genomic and Single‐Cell Analysis Reveals Heterogeneity, Prognosis, and Treatment Vulnerability in Urothelial Carcinoma
Human Mutation · 2026-01 · 2026 (1)
DOI: 10.1155/humu/2797474 ↗Abstract
At the transcriptomic level, several molecular subtyping schemes have been established to elucidate the intrinsic heterogeneity of urothelial carcinoma and to inform prognostic assessment and therapeutic guidance. However, a unified molecular classification scheme characterizing genomic alterations is lacking. Unsupervised and supervised clustering identified two distinct mutational signature subtypes. Kaplan–Meier analysis demonstrated that patients with the MUT2 subtype had a higher risk of death than those with the MUT1 subtype across multiple cohorts, including IMvigor210 (hazard ratio [HR], 1.74; 95% confidence interval [CI], 1.27–2.37; p < 0.001), UC‐GENOME (HR, 1.54; 95% CI, 0.93–2.54; p = 0.091), The Cancer Genome Atlas (TCGA; HR, 1.45; 95% CI, 1.06–1.98; p = 0.020), MSK2022 (HR, 1.34; 95% CI, 1.10–1.64; p = 0.004), MSK2015 (HR, 3.43; 95% CI, 1.36–8.64; p = 0.005), and the Tongji cohort (HR, 4.99; 95% CI, 0.57–43.69; p = 0.11). Immunotherapy response rates were significantly higher in the MUT1 subtype than in the MUT2 subtype in IMvigor210 (31.8% vs. 13.1%; p = 0.003) and UC‐GENOME (42.3% vs. 29.0%; p = 0.022). Consistent with these findings, single‐cell analysis showed that MUT2 tumors were enriched in tumor‐associated fibroblast subpopulations and had a lower abundance of immune effector cells. Overall, this genomic analysis identified two mutation‐based subtypes of urothelial carcinoma associated with patient prognosis and immunotherapy response.
EUVIMED